Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Short-term Investments (2016 - 2026)

United Therapeutics' Short-term Investments history spans 17 years, with the latest figure at $1.4 billion for Q4 2025.

  • On a quarterly basis, Short-term Investments fell 13.16% to $1.4 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.4 billion, a 13.16% decrease, with the full-year FY2025 number at $1.4 billion, down 13.16% from a year prior.
  • Short-term Investments hit $1.4 billion in Q4 2025 for United Therapeutics, down from $1.4 billion in the prior quarter.
  • Over the last five years, Short-term Investments for UTHR hit a ceiling of $1.9 billion in Q4 2022 and a floor of $899.0 million in Q1 2021.
  • Historically, Short-term Investments has averaged $1.5 billion across 5 years, with a median of $1.5 billion in 2022.
  • Biggest five-year swings in Short-term Investments: surged 81.24% in 2022 and later dropped 19.47% in 2025.
  • Tracing UTHR's Short-term Investments over 5 years: stood at $1.0 billion in 2021, then surged by 81.24% to $1.9 billion in 2022, then decreased by 4.85% to $1.8 billion in 2023, then dropped by 12.12% to $1.6 billion in 2024, then dropped by 13.16% to $1.4 billion in 2025.
  • Business Quant data shows Short-term Investments for UTHR at $1.4 billion in Q4 2025, $1.4 billion in Q3 2025, and $1.5 billion in Q2 2025.